Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

June 7, 2025
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • FEATURED
  • Recent studies show certain Microbiota treatments are backfiring!

Genetic reprogramming - the cellular machinery of yeast to create factories that convert sugars and amino acids into plant-based drugs

JNU | JRF position |DBT funded Project

Recent studies show certain Microbiota treatments are backfiring!
  • BiotechToday
  • FEATURED
  • World

Recent studies show certain Microbiota treatments are backfiring!

bioxone September 7, 2020September 7, 2020

–Raddur Samaddar, Amity University Kolkata

Hypoxia is the talk of the town now, especially with the advent of COVID-19, curing of patients with severe levels of infection, escalating to respiratory problems, with oxygen-induced treatment is a major form of supportive care. Scientists have come up with a study that provides information on gut microbiota and their contribution to severe Hypoxia.

Up till now, we were confident about the fact that oxygen is the most important treatment ‘drug’ and any drug of choice has to be used in the correct dosage for treatment. The study has been performed with all the important parameters such as Comparative study with Human and Mice models, the dysbiosis in lungs, the correlations among hypoxia, the cecal microbiota composition, and alveolar inflammation with the antibiotic treatment and its effects. In untreated mice, treatment with excessive amounts of oxygen leads to a change in the mice’s microbiota, and a rise in the population of the Staphylococcus species was noted. It was inferred that such population alterations of the microbes were precursive to the onset of inflammation.

The aim of the study is to show how Hypoxia alters the microbiota growth conditions and also how a microbe-free environment is actually helping in the treatment. The harm we knew we were causing will be now proved from a therapeutic standpoint and we can alter the microbiota accordingly. Successive experiments would find out how such microbial manipulations would work.

Source: Lung and gut microbiota are altered by hyperoxia and contribute to oxygen-induced lung injury in mice. Ashley, S. L., Sjoding, M. W., Popova, A. P., Cui, T. X., Hoostal, M. J., Schmidt, T. M., Branton, W. R., Dieterle, M. G., Falkowski, N. R., Baker, J. M., Hinkle, K. J., Konopka, K. E., Erb-Downward, J. R., Huffnagle, G. B., & Dickson, R. P. (2020). Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aau9959,

https://stm.sciencemag.org/content/12/556/eaau9959/tab-pdf

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Related

Tagged Covid Hypoxia Microbiota

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

JNU | JRF position |DBT funded Project

bioxone September 7, 2020

–Shristi Sharma, Amity University Kolkata Applications are invited for ONE Junior Research Fellow in the DBT funded project entitled “Study of in-depth genetic heterogeneity with respect to resistome and compensatory adaption of MDR Mtb clinical strains inside BM-Mesenchymal stem cells circulating in the North-East Region” in the laboratory of the undersigned. Salary: Rs.31,000/- per month + 24% HRA Essential Qualification: Post […]

Related Post

  • BiotechToday
  • World

Metabolomics: A tool to measure metabolites in the Gut microbiome

bioxone August 9, 2021August 8, 2021

Jerry John, D.Y Patil University There are about 100 trillion micro-organisms in the human gastrointestinal tract. Most of these organisms include bacteria, and some are fungi, protozoa, and viruses. The collective genome of these micro-organisms is known as the microbiome. About:  From 23,000 genes of the human genome, 3 million genes encode for the microbiome. […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • World

Association of kidney and liver biomarkers with MetS

bioxone July 28, 2021July 27, 2021

Madhavi Bhatia, National Institute of Pharmaceutical Education and Research, Guwahati Metabolic syndrome (MetS) is a group of cardiometabolic conditions that are leading contributors to an elevated risk for cardiovascular disease (CVD) and type II diabetes. Many consequences have been identified which occur due to MetS, an increased risk of fatty liver disease, renal disease, and […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • World

VV116 vs. Nirmatrelvir-Ritonavir Against COVID-19

DNA tales April 23, 2023April 23, 2023

Tholkappian R, NIT Durgapur Nirmatrelvir is an oral inhibitor of the SARS-CoV-2’s, 3-chymotrypsin–like cysteine protease, while VV116 is a deuterated remdesivir hydro-bromide with potent activity against SARS-CoV-2. Nirmatrelvir-ritonavir was used to treat COVID-19 of low to moderate severity. However, its production could not meet the global supply demands. VV116 is one such oral analog of […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy